Co-careldopa intestinal gel (Duodopa®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000459
English
Authors' recommendations:
Co-careldopa intestinal gel (Duodopa®) should not be recommended for use within NHS Wales for the treatment of advanced levodopa-responsive Parkinson's disease. The clinical and cost effectiveness data presented was not sufficient for AWMSG to recommend its use.
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=85966&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Carbidopa
- Adjuvants, Immunologic
- Antiparkinson Agents
- Parkinson Disease
- Levodopa
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.